dpp-4 inhibitor and glp-1 receptor agonist combination Frontiers Role of Dipeptidyl Peptidase 4

This finding aligns with evidence from large trials in T2DMsuch as LEADER, REWIND, and AMPLITUDE-Owhich reported death reductions ranging from 12 to 22% [10, 22]

De Jonghe

These include mitigation of hyperglycemia, overweight and insulin resistance, systemic and glomerular hypertension, dyslipidemia, sodium retention, inflammation and renal hypoxia

Perspectives and conclusions Tirzepatide has demonstrated marked and dose-dependent reductions in glycemic parameters in patients with T2D that, according to the present study data, surpass the effects of the GLP-1RA dulaglutide and semaglutide (54, 66, 67, 71)

Journal of clinical medicine , 12 (18), 5915

Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, et al